Ascentage Reports Bcl-2 Inhibitor Effective in Early Test

Ascentage Pharma, a Suzhou company, reported promising data from an early test of its Bcl-2 inhibitor in hematologic malignancies. Lisaftoclax (APG-2575) showed an objective response rate of 80% in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and other hematologic malignancies. Previously, patients had received a median of two treatments for their disease. The results were reported in an oral presentation at the 57th ASCO Annual Meeting, one of four Ascentage presentations at the meeting. More details.... Stock Symbol: (HK: 6855) Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.